Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zotiraciclib - Adastra Pharmaceuticals/S*Bio

Next Previous
Drug Profile

Zotiraciclib - Adastra Pharmaceuticals/S*Bio

Alternative Names: SB-1317; TG 02 - S*Bio/Adastra-Pharmaceuticals; TG02; TG02 citrate; Zotiraciclib citrate

Latest Information Update: 08 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator S*BIO
  • Developer Adastra Pharmaceuticals; European Organisation for Research and Treatment of Cancer; Lee's Pharmaceutical; National Cancer Institute (USA); S*BIO
  • Class Antineoplastics; Heterocyclic compounds with 4 or more rings; Small molecules
  • Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 5 inhibitors; Cyclin-dependent kinase 9 inhibitors; Extracellular signal-regulated MAP kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Janus kinase 2 inhibitors; RNA polymerase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Anaplastic astrocytoma; Glioblastoma
  • No development reported Cancer; Chronic lymphocytic leukaemia; Diffuse intrinsic pontine glioma; Leukaemia; Multiple myeloma; Solid tumours

Most Recent Events

  • 23 Feb 2026 National Cancer Institute terminates a phase I/II trial in Anaplastic astrocytoma (Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) and Glioblastoma (Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (PO) as the company was unable to supply investigational agent (NCT02942264)
  • 02 Jun 2023 Efficacy and adverse events data from the phase Ib STEAM trial for Anaplastic astrocytoma and Glioblastoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 03 Nov 2022 National Cancer Institute plans a phase I/II trial in Glioma (Recurrent, Second-line therapy or greater) in USA (PO) (NCT05588141)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top